Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
Option to license Perspective Therapeutics’ Pb212-VMT-α-NET asset
Co-development rights for certain Pb212-based alpha therapies for prostate cancer
Related news for (LNTH)
- Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
- Lantheus Announces CEO Succession Plan
- Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
- Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference